New York, May 03, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Vancomycin Industry" - https://www.reportlinker.com/p06033216/?utm_source=GNW
Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Global Vancomycin Market to Reach $555.5 Million by 2030
In the changed post COVID-19 business landscape, the global market for Vancomycin estimated at US$477.3 Million in the year 2022, is projected to reach a revised size of US$555.5 Million by 2030, growing at aCAGR of 1.9% over the period 2022-2030. Lung Infection, one of the segments analyzed in the report, is projected to record 3.4% CAGR and reach US$201.9 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Sepsis segment is readjusted to a revised 2.2% CAGR for the next 8-year period.
The U.S. Market is Estimated at $130 Million, While China is Forecast to Grow at 6.3% CAGR
The Vancomycin market in the U.S. is estimated at US$130 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$130.4 Million by the year 2030 trailing a CAGR of 6.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at -1.1% and 0.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 0% CAGR.
Select Competitors (Total 12 Featured)
- Alchemia Limited
- Alvogen
- Aphios Corporation
- Cellceutix Corporation
- CJ CheilJedang
- Eli Lilly and Company
- Enanta Pharmaceuticals
- Helix BioMedix
- LegoChem Biosciences
- Lytix Biopharma
Read the full report: https://www.reportlinker.com/p06033216/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Vancomycin - Global Key Competitors Percentage Market Share in
2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Vancomycin Market Analysis of Annual Sales in
US$ Thousand for Years 2014 through 2030
Table 2: World Recent Past, Current & Future Analysis for
Vancomycin by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2022 through 2030 and % CAGR
Table 3: World Historic Review for Vancomycin by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2014 through 2021 and
% CAGR
Table 4: World 16-Year Perspective for Vancomycin by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets for Years 2014, 2023 & 2030
Table 5: World Recent Past, Current & Future Analysis for Lung
Infection by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2022 through 2030 and % CAGR
Table 6: World Historic Review for Lung Infection by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2014 through 2021 and
% CAGR
Table 7: World 16-Year Perspective for Lung Infection by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 8: World Recent Past, Current & Future Analysis for
Sepsis by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2022 through 2030 and % CAGR
Table 9: World Historic Review for Sepsis by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2014 through 2021 and
% CAGR
Table 10: World 16-Year Perspective for Sepsis by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030
Table 11: World Recent Past, Current & Future Analysis for
Colitis & Intestinal Inflammation by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
Table 12: World Historic Review for Colitis & Intestinal
Inflammation by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2014 through 2021 and % CAGR
Table 13: World 16-Year Perspective for Colitis & Intestinal
Inflammation by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2014, 2023 & 2030
Table 14: World Recent Past, Current & Future Analysis for Skin
Soft Tissue Infection by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2022 through 2030 and % CAGR
Table 15: World Historic Review for Skin Soft Tissue Infection
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR
Table 16: World 16-Year Perspective for Skin Soft Tissue
Infection by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2014, 2023 &
2030
Table 17: World Recent Past, Current & Future Analysis for
Other Applications by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2022 through 2030 and % CAGR
Table 18: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR
Table 19: World 16-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
III. MARKET ANALYSIS
UNITED STATES
Vancomycin Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in the United States for 2023 (E)
Table 20: USA Recent Past, Current & Future Analysis for
Vancomycin by Application - Lung Infection, Sepsis, Colitis &
Intestinal Inflammation, Skin Soft Tissue Infection and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 21: USA Historic Review for Vancomycin by Application -
Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin
Soft Tissue Infection and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR
Table 22: USA 16-Year Perspective for Vancomycin by Application -
Percentage Breakdown of Value Sales for Lung Infection,
Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue
Infection and Other Applications for the Years 2014, 2023 &
2030
CANADA
Table 23: Canada Recent Past, Current & Future Analysis for
Vancomycin by Application - Lung Infection, Sepsis, Colitis &
Intestinal Inflammation, Skin Soft Tissue Infection and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 24: Canada Historic Review for Vancomycin by Application -
Lung Infection, Sepsis, Colitis & Intestinal Inflammation,
Skin Soft Tissue Infection and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR
Table 25: Canada 16-Year Perspective for Vancomycin by
Application - Percentage Breakdown of Value Sales for Lung
Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft
Tissue Infection and Other Applications for the Years 2014,
2023 & 2030
JAPAN
Vancomycin Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in Japan for 2023 (E)
Table 26: Japan Recent Past, Current & Future Analysis for
Vancomycin by Application - Lung Infection, Sepsis, Colitis &
Intestinal Inflammation, Skin Soft Tissue Infection and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 27: Japan Historic Review for Vancomycin by Application -
Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin
Soft Tissue Infection and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR
Table 28: Japan 16-Year Perspective for Vancomycin by
Application - Percentage Breakdown of Value Sales for Lung
Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft
Tissue Infection and Other Applications for the Years 2014,
2023 & 2030
CHINA
Vancomycin Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in China for 2023 (E)
Table 29: China Recent Past, Current & Future Analysis for
Vancomycin by Application - Lung Infection, Sepsis, Colitis &
Intestinal Inflammation, Skin Soft Tissue Infection and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 30: China Historic Review for Vancomycin by Application -
Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin
Soft Tissue Infection and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR
Table 31: China 16-Year Perspective for Vancomycin by
Application - Percentage Breakdown of Value Sales for Lung
Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft
Tissue Infection and Other Applications for the Years 2014,
2023 & 2030
EUROPE
Vancomycin Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in Europe for 2023 (E)
Table 32: Europe Recent Past, Current & Future Analysis for
Vancomycin by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2022 through 2030 and
% CAGR
Table 33: Europe Historic Review for Vancomycin by Geographic
Region - France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2014 through 2021 and % CAGR
Table 34: Europe 16-Year Perspective for Vancomycin by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2014, 2023 & 2030
Table 35: Europe Recent Past, Current & Future Analysis for
Vancomycin by Application - Lung Infection, Sepsis, Colitis &
Intestinal Inflammation, Skin Soft Tissue Infection and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 36: Europe Historic Review for Vancomycin by Application -
Lung Infection, Sepsis, Colitis & Intestinal Inflammation,
Skin Soft Tissue Infection and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR
Table 37: Europe 16-Year Perspective for Vancomycin by
Application - Percentage Breakdown of Value Sales for Lung
Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft
Tissue Infection and Other Applications for the Years 2014,
2023 & 2030
FRANCE
Vancomycin Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in France for 2023 (E)
Table 38: France Recent Past, Current & Future Analysis for
Vancomycin by Application - Lung Infection, Sepsis, Colitis &
Intestinal Inflammation, Skin Soft Tissue Infection and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 39: France Historic Review for Vancomycin by Application -
Lung Infection, Sepsis, Colitis & Intestinal Inflammation,
Skin Soft Tissue Infection and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR
Table 40: France 16-Year Perspective for Vancomycin by
Application - Percentage Breakdown of Value Sales for Lung
Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft
Tissue Infection and Other Applications for the Years 2014,
2023 & 2030
GERMANY
Vancomycin Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in Germany for 2023 (E)
Table 41: Germany Recent Past, Current & Future Analysis for
Vancomycin by Application - Lung Infection, Sepsis, Colitis &
Intestinal Inflammation, Skin Soft Tissue Infection and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 42: Germany Historic Review for Vancomycin by Application -
Lung Infection, Sepsis, Colitis & Intestinal Inflammation,
Skin Soft Tissue Infection and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR
Table 43: Germany 16-Year Perspective for Vancomycin by
Application - Percentage Breakdown of Value Sales for Lung
Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft
Tissue Infection and Other Applications for the Years 2014,
2023 & 2030
ITALY
Table 44: Italy Recent Past, Current & Future Analysis for
Vancomycin by Application - Lung Infection, Sepsis, Colitis &
Intestinal Inflammation, Skin Soft Tissue Infection and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 45: Italy Historic Review for Vancomycin by Application -
Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin
Soft Tissue Infection and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR
Table 46: Italy 16-Year Perspective for Vancomycin by
Application - Percentage Breakdown of Value Sales for Lung
Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft
Tissue Infection and Other Applications for the Years 2014,
2023 & 2030
UNITED KINGDOM
Vancomycin Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in the United Kingdom for 2023 (E)
Table 47: UK Recent Past, Current & Future Analysis for
Vancomycin by Application - Lung Infection, Sepsis, Colitis &
Intestinal Inflammation, Skin Soft Tissue Infection and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 48: UK Historic Review for Vancomycin by Application -
Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin
Soft Tissue Infection and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR
Table 49: UK 16-Year Perspective for Vancomycin by Application -
Percentage Breakdown of Value Sales for Lung Infection,
Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue
Infection and Other Applications for the Years 2014, 2023 &
2030
SPAIN
Table 50: Spain Recent Past, Current & Future Analysis for
Vancomycin by Application - Lung Infection, Sepsis, Colitis &
Intestinal Inflammation, Skin Soft Tissue Infection and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 51: Spain Historic Review for Vancomycin by Application -
Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin
Soft Tissue Infection and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR
Table 52: Spain 16-Year Perspective for Vancomycin by
Application - Percentage Breakdown of Value Sales for Lung
Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft
Tissue Infection and Other Applications for the Years 2014,
2023 & 2030
RUSSIA
Table 53: Russia Recent Past, Current & Future Analysis for
Vancomycin by Application - Lung Infection, Sepsis, Colitis &
Intestinal Inflammation, Skin Soft Tissue Infection and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 54: Russia Historic Review for Vancomycin by Application -
Lung Infection, Sepsis, Colitis & Intestinal Inflammation,
Skin Soft Tissue Infection and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR
Table 55: Russia 16-Year Perspective for Vancomycin by
Application - Percentage Breakdown of Value Sales for Lung
Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft
Tissue Infection and Other Applications for the Years 2014,
2023 & 2030
REST OF EUROPE
Table 56: Rest of Europe Recent Past, Current & Future Analysis
for Vancomycin by Application - Lung Infection, Sepsis, Colitis &
Intestinal Inflammation, Skin Soft Tissue Infection and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 57: Rest of Europe Historic Review for Vancomycin by
Application - Lung Infection, Sepsis, Colitis & Intestinal
Inflammation, Skin Soft Tissue Infection and Other Applications
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2014 through 2021 and % CAGR
Table 58: Rest of Europe 16-Year Perspective for Vancomycin by
Application - Percentage Breakdown of Value Sales for Lung
Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft
Tissue Infection and Other Applications for the Years 2014,
2023 & 2030
ASIA-PACIFIC
Vancomycin Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in Asia-Pacific for 2023 (E)
Table 59: Asia-Pacific Recent Past, Current & Future Analysis
for Vancomycin by Geographic Region - Australia, India, South
Korea and Rest of Asia-Pacific Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2022 through 2030 and
% CAGR
Table 60: Asia-Pacific Historic Review for Vancomycin by
Geographic Region - Australia, India, South Korea and Rest of
Asia-Pacific Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2014 through 2021 and % CAGR
Table 61: Asia-Pacific 16-Year Perspective for Vancomycin by
Geographic Region - Percentage Breakdown of Value Sales for
Australia, India, South Korea and Rest of Asia-Pacific Markets
for Years 2014, 2023 & 2030
Table 62: Asia-Pacific Recent Past, Current & Future Analysis
for Vancomycin by Application - Lung Infection, Sepsis, Colitis &
Intestinal Inflammation, Skin Soft Tissue Infection and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 63: Asia-Pacific Historic Review for Vancomycin by
Application - Lung Infection, Sepsis, Colitis & Intestinal
Inflammation, Skin Soft Tissue Infection and Other Applications
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2014 through 2021 and % CAGR
Table 64: Asia-Pacific 16-Year Perspective for Vancomycin by
Application - Percentage Breakdown of Value Sales for Lung
Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft
Tissue Infection and Other Applications for the Years 2014,
2023 & 2030
AUSTRALIA
Vancomycin Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in Australia for 2023 (E)
Table 65: Australia Recent Past, Current & Future Analysis for
Vancomycin by Application - Lung Infection, Sepsis, Colitis &
Intestinal Inflammation, Skin Soft Tissue Infection and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 66: Australia Historic Review for Vancomycin by
Application - Lung Infection, Sepsis, Colitis & Intestinal
Inflammation, Skin Soft Tissue Infection and Other Applications
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2014 through 2021 and % CAGR
Table 67: Australia 16-Year Perspective for Vancomycin by
Application - Percentage Breakdown of Value Sales for Lung
Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft
Tissue Infection and Other Applications for the Years 2014,
2023 & 2030
INDIA
Vancomycin Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in India for 2023 (E)
Table 68: India Recent Past, Current & Future Analysis for
Vancomycin by Application - Lung Infection, Sepsis, Colitis &
Intestinal Inflammation, Skin Soft Tissue Infection and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 69: India Historic Review for Vancomycin by Application -
Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin
Soft Tissue Infection and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR
Table 70: India 16-Year Perspective for Vancomycin by
Application - Percentage Breakdown of Value Sales for Lung
Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft
Tissue Infection and Other Applications for the Years 2014,
2023 & 2030
SOUTH KOREA
Table 71: South Korea Recent Past, Current & Future Analysis
for Vancomycin by Application - Lung Infection, Sepsis, Colitis &
Intestinal Inflammation, Skin Soft Tissue Infection and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 72: South Korea Historic Review for Vancomycin by
Application - Lung Infection, Sepsis, Colitis & Intestinal
Inflammation, Skin Soft Tissue Infection and Other Applications
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2014 through 2021 and % CAGR
Table 73: South Korea 16-Year Perspective for Vancomycin by
Application - Percentage Breakdown of Value Sales for Lung
Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft
Tissue Infection and Other Applications for the Years 2014,
2023 & 2030
REST OF ASIA-PACIFIC
Table 74: Rest of Asia-Pacific Recent Past, Current & Future
Analysis for Vancomycin by Application - Lung Infection,
Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue
Infection and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2022 through 2030
and % CAGR
Table 75: Rest of Asia-Pacific Historic Review for Vancomycin
by Application - Lung Infection, Sepsis, Colitis & Intestinal
Inflammation, Skin Soft Tissue Infection and Other Applications
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2014 through 2021 and % CAGR
Table 76: Rest of Asia-Pacific 16-Year Perspective for
Vancomycin by Application - Percentage Breakdown of Value Sales
for Lung Infection, Sepsis, Colitis & Intestinal Inflammation,
Skin Soft Tissue Infection and Other Applications for the Years
2014, 2023 & 2030
LATIN AMERICA
Vancomycin Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in Latin America for 2023 (E)
Table 77: Latin America Recent Past, Current & Future Analysis
for Vancomycin by Geographic Region - Argentina, Brazil, Mexico
and Rest of Latin America Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2022 through 2030 and %
CAGR
Table 78: Latin America Historic Review for Vancomycin by
Geographic Region - Argentina, Brazil, Mexico and Rest of Latin
America Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2014 through 2021 and % CAGR
Table 79: Latin America 16-Year Perspective for Vancomycin by
Geographic Region - Percentage Breakdown of Value Sales for
Argentina, Brazil, Mexico and Rest of Latin America Markets for
Years 2014, 2023 & 2030
Table 80: Latin America Recent Past, Current & Future Analysis
for Vancomycin by Application - Lung Infection, Sepsis, Colitis &
Intestinal Inflammation, Skin Soft Tissue Infection and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 81: Latin America Historic Review for Vancomycin by
Application - Lung Infection, Sepsis, Colitis & Intestinal
Inflammation, Skin Soft Tissue Infection and Other Applications
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2014 through 2021 and % CAGR
Table 82: Latin America 16-Year Perspective for Vancomycin by
Application - Percentage Breakdown of Value Sales for Lung
Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft
Tissue Infection and Other Applications for the Years 2014,
2023 & 2030
ARGENTINA
Table 83: Argentina Recent Past, Current & Future Analysis for
Vancomycin by Application - Lung Infection, Sepsis, Colitis &
Intestinal Inflammation, Skin Soft Tissue Infection and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 84: Argentina Historic Review for Vancomycin by
Application - Lung Infection, Sepsis, Colitis & Intestinal
Inflammation, Skin Soft Tissue Infection and Other Applications
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2014 through 2021 and % CAGR
Table 85: Argentina 16-Year Perspective for Vancomycin by
Application - Percentage Breakdown of Value Sales for Lung
Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft
Tissue Infection and Other Applications for the Years 2014,
2023 & 2030
BRAZIL
Table 86: Brazil Recent Past, Current & Future Analysis for
Vancomycin by Application - Lung Infection, Sepsis, Colitis &
Intestinal Inflammation, Skin Soft Tissue Infection and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 87: Brazil Historic Review for Vancomycin by Application -
Lung Infection, Sepsis, Colitis & Intestinal Inflammation,
Skin Soft Tissue Infection and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR
Table 88: Brazil 16-Year Perspective for Vancomycin by
Application - Percentage Breakdown of Value Sales for Lung
Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft
Tissue Infection and Other Applications for the Years 2014,
2023 & 2030
MEXICO
Table 89: Mexico Recent Past, Current & Future Analysis for
Vancomycin by Application - Lung Infection, Sepsis, Colitis &
Intestinal Inflammation, Skin Soft Tissue Infection and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 90: Mexico Historic Review for Vancomycin by Application -
Lung Infection, Sepsis, Colitis & Intestinal Inflammation,
Skin Soft Tissue Infection and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR
Table 91: Mexico 16-Year Perspective for Vancomycin by
Application - Percentage Breakdown of Value Sales for Lung
Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft
Tissue Infection and Other Applications for the Years 2014,
2023 & 2030
REST OF LATIN AMERICA
Table 92: Rest of Latin America Recent Past, Current & Future
Analysis for Vancomycin by Application - Lung Infection,
Sepsis, Colitis & Intestinal Inflammation, Skin Soft Tissue
Infection and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2022 through 2030
and % CAGR
Table 93: Rest of Latin America Historic Review for Vancomycin
by Application - Lung Infection, Sepsis, Colitis & Intestinal
Inflammation, Skin Soft Tissue Infection and Other Applications
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2014 through 2021 and % CAGR
Table 94: Rest of Latin America 16-Year Perspective for
Vancomycin by Application - Percentage Breakdown of Value Sales
for Lung Infection, Sepsis, Colitis & Intestinal Inflammation,
Skin Soft Tissue Infection and Other Applications for the Years
2014, 2023 & 2030
MIDDLE EAST
Vancomycin Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in Middle East for 2023 (E)
Table 95: Middle East Recent Past, Current & Future Analysis
for Vancomycin by Geographic Region - Iran, Israel, Saudi
Arabia, UAE and Rest of Middle East Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2022 through
2030 and % CAGR
Table 96: Middle East Historic Review for Vancomycin by
Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of
Middle East Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2014 through 2021 and % CAGR
Table 97: Middle East 16-Year Perspective for Vancomycin by
Geographic Region - Percentage Breakdown of Value Sales for
Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets
for Years 2014, 2023 & 2030
Table 98: Middle East Recent Past, Current & Future Analysis
for Vancomycin by Application - Lung Infection, Sepsis, Colitis &
Intestinal Inflammation, Skin Soft Tissue Infection and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 99: Middle East Historic Review for Vancomycin by
Application - Lung Infection, Sepsis, Colitis & Intestinal
Inflammation, Skin Soft Tissue Infection and Other Applications
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2014 through 2021 and % CAGR
Table 100: Middle East 16-Year Perspective for Vancomycin by
Application - Percentage Breakdown of Value Sales for Lung
Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft
Tissue Infection and Other Applications for the Years 2014,
2023 & 2030
IRAN
Table 101: Iran Recent Past, Current & Future Analysis for
Vancomycin by Application - Lung Infection, Sepsis, Colitis &
Intestinal Inflammation, Skin Soft Tissue Infection and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 102: Iran Historic Review for Vancomycin by Application -
Lung Infection, Sepsis, Colitis & Intestinal Inflammation, Skin
Soft Tissue Infection and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR
Table 103: Iran 16-Year Perspective for Vancomycin by
Application - Percentage Breakdown of Value Sales for Lung
Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft
Tissue Infection and Other Applications for the Years 2014,
2023 & 2030
ISRAEL
Table 104: Israel Recent Past, Current & Future Analysis for
Vancomycin by Application - Lung Infection, Sepsis, Colitis &
Intestinal Inflammation, Skin Soft Tissue Infection and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 105: Israel Historic Review for Vancomycin by Application -
Lung Infection, Sepsis, Colitis & Intestinal Inflammation,
Skin Soft Tissue Infection and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR
Table 106: Israel 16-Year Perspective for Vancomycin by
Application - Percentage Breakdown of Value Sales for Lung
Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft
Tissue Infection and Other Applications for the Years 2014,
2023 & 2030
SAUDI ARABIA
Table 107: Saudi Arabia Recent Past, Current & Future Analysis
for Vancomycin by Application - Lung Infection, Sepsis, Colitis &
Intestinal Inflammation, Skin Soft Tissue Infection and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 108: Saudi Arabia Historic Review for Vancomycin by
Application - Lung Infection, Sepsis, Colitis & Intestinal
Inflammation, Skin Soft Tissue Infection and Other Applications
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2014 through 2021 and % CAGR
Table 109: Saudi Arabia 16-Year Perspective for Vancomycin by
Application - Percentage Breakdown of Value Sales for Lung
Infection, Sepsis, Colitis & Intestinal Inflammation, Skin Soft
Tissue Infection and Other Applications for the Years 2014,
2023 & 2030
UNITED ARAB EMIRATES
Table 110: UAE Recent Past, Current & Future Analysis for
Vancomycin by Application - Lung Infection, Sepsis, Colitis &
Intestinal Inflammation, Skin Soft Tissue Infection and Other
Applications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR
Table 111: UAE Historic Review for Vancomycin by Application -
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06033216/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
